|
1
|
Modulators of arginine metabolism support cancer immunosurveillance.
|
BMC Immunol
|
2009
|
1.61
|
|
2
|
Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors.
|
Stem Cells Transl Med
|
2013
|
1.50
|
|
3
|
Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes.
|
Cancer Res
|
2012
|
1.41
|
|
4
|
Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.
|
Eur J Immunol
|
2005
|
1.29
|
|
5
|
Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
|
Cancer Res
|
2008
|
1.20
|
|
6
|
Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy.
|
J Immunol
|
2012
|
1.17
|
|
7
|
Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes.
|
Cancer Res
|
2003
|
0.95
|
|
8
|
Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses.
|
Oncoimmunology
|
2013
|
0.93
|
|
9
|
Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings.
|
Cancer Res
|
2013
|
0.93
|
|
10
|
iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells.
|
PLoS One
|
2010
|
0.91
|
|
11
|
Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.
|
Prostate
|
2008
|
0.89
|
|
12
|
Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer.
|
Clin Cancer Res
|
2011
|
0.82
|
|
13
|
Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors.
|
Cancer Res
|
2010
|
0.79
|
|
14
|
Type 2 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type 2 immune responses.
|
J Immunol
|
2006
|
0.78
|
|
15
|
Boosting anticancer vaccines: Too much of a good thing?
|
Oncoimmunology
|
2013
|
0.76
|
|
16
|
Prolonged exposure of dendritic cells to maturation stimuli favors the induction of type-2 cytotoxic T lymphocytes.
|
Eur J Immunol
|
2006
|
0.76
|